KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Research & Development (2016 - 2026)

West Pharmaceutical Services has reported Research & Development over the past 18 years, most recently at $15.8 million for Q1 2026.

  • Quarterly Research & Development fell 3.07% to $15.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $73.8 million through Mar 2026, up 8.85% year-over-year, with the annual reading at $74.3 million for FY2025, 7.53% up from the prior year.
  • Research & Development was $15.8 million for Q1 2026 at West Pharmaceutical Services, down from $21.8 million in the prior quarter.
  • Over five years, Research & Development peaked at $21.8 million in Q4 2025 and troughed at $13.6 million in Q3 2022.
  • The 5-year median for Research & Development is $16.5 million (2023), against an average of $16.8 million.
  • Biggest five-year swings in Research & Development: rose 20.59% in 2023 and later fell 7.39% in 2025.
  • Tracing WST's Research & Development over 5 years: stood at $15.9 million in 2022, then grew by 15.72% to $18.4 million in 2023, then rose by 0.54% to $18.5 million in 2024, then increased by 17.84% to $21.8 million in 2025, then dropped by 27.52% to $15.8 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $15.8 million, $21.8 million, and $17.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.